1. Home
  2. KOSS vs VERU Comparison

KOSS vs VERU Comparison

Compare KOSS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

N/A

Current Price

$4.33

Market Cap

39.3M

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.25

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
VERU
Founded
1953
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.3M
40.9M
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
KOSS
VERU
Price
$4.33
$2.25
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
25.2K
51.2K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
10.00
N/A
EPS
N/A
N/A
Revenue
$12,624,170.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.93
N/A
52 Week Low
$3.50
$0.36
52 Week High
$8.59
$4.59

Technical Indicators

Market Signals
Indicator
KOSS
VERU
Relative Strength Index (RSI) 63.28 41.14
Support Level $4.18 $2.13
Resistance Level $4.91 $2.67
Average True Range (ATR) 0.25 0.10
MACD 0.03 -0.02
Stochastic Oscillator 62.51 12.96

Price Performance

Historical Comparison
KOSS
VERU

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: